KẾT QUẢ ĐIỀU TRỊ UNG THƯ BÀNG QUANG NÔNG BẰNG BCG NỘI BÀNG QUANG TẠI BỆNH VIỆN K

Abstract

Objective: Describe some clinical and subclinical characteristics of patients and evaluate treatment outcomes of non-muscle invasive bladder cancer (NMIBC) treated with adjuvant intravesical BCG therapy at K Hospital. Patients and Research Method: A descriptive, case-cluster-study was conducted on 82 newly diagnosed NMIBC patients who underwent transurethral resection of bladder tumors (TURBT) and received adjuvant intravesical BCG therapy at K Hospital from April 2015 to December 2020. Results: A total of 82 NMIBC patients were included in the study, with a mean age of 56.8 ± 13.7, ranging from 23 to 84 years old. The male-to-female ratio was 6.45. The most common reason for hospital admission was hematuria (76.8%). In this study, 72% of patients had a single solitary tumor in the bladder, 12.1% had the largest tumor size over 3 cm, and 47.6% had tumors with a stalk. The majority of patients were in stage T1, accounting for 56.1%. The high-risk group accounted for 43.9% and had high histological grades. During a mean follow-up period of 48.2 months, tumor recurrence occurred in 14.6% of patients, requiring repeat TURBT. Disease progression to invasive stage occurred in 4.9% of patients, who then underwent radical cystectomy. The most common adverse events were dysuria (31.7%), hematuria (11%), urgency (7.3%), and high fever (1.2%). Conclusion: Adjuvant intravesical BCG immunotherapy is highly effective and safe in non-muscle-invasive bladder cancer patients who have undergone TURBT, reducing the rates of recurrence and progression.